What is Singulex?
Founded in 1997 and headquartered in Alameda, California, Singulex is at the forefront of developing and providing single-molecule counting technology. This innovative platform is designed for critical applications in clinical diagnostics and scientific discovery, offering unparalleled sensitivity and precision. The company's technology aims to revolutionize how diseases are detected and monitored, enabling earlier and more accurate diagnoses. Singulex's commitment to advancing diagnostic capabilities positions it as a key player in the healthcare technology landscape.
How much funding has Singulex raised?
Singulex has raised a total of $151.8M across 6 funding rounds:
Series C
$8.4M
Series D
$19M
Series E
$19M
Series F
$15.3M
Debt
$40M
Private Equity
$50M
Series C (2006): $8.4M with participation from BioProfile Holding Company, Fisk Ventures, and Prolog Capital
Series D (2009): $19M led by Jafco ventures and OrbiMed
Series E (2009): $19M supported by JAFCO Japan, Fisk Ventures, and OrbiMed
Series F (2012): $15.3M, investors not publicly disclosed
Debt (2013): $40M backed by Silicon Valley Bank and Oxford Finance
Private Equity (2016): $50M with participation from Grifols
Key Investors in Singulex
Grifols
Grifols is a global healthcare company based in Barcelona, Spain, specializing in plasma-derived medicines, diagnostics, and hospital products. Their investment in Singulex suggests a strategic interest in advancing diagnostic technologies that complement their existing portfolio.
Silicon Valley Bank
Silicon Valley Bank (SVB) is a financial institution that provides commercial and private banking services, asset management, and investment services, particularly to technology and life science companies. Their participation indicates confidence in Singulex's technological innovation and market potential.
Oxford Finance
Oxford Finance is a specialty finance firm offering financial solutions to healthcare and life sciences companies. Their involvement points to Singulex's strong position within the life sciences sector and its need for growth capital.
What's next for Singulex?
With the recent influx of major strategic investment, Singulex is poised for significant expansion. The company is likely to focus on scaling its operations, enhancing its technological capabilities, and broadening its market reach. This funding will be instrumental in driving further research and development, potentially leading to new diagnostic assays and applications. Strategic partnerships and market penetration will be key areas of focus as Singulex leverages this capital to solidify its leadership in the single-molecule counting technology space and address unmet needs in clinical diagnostics.
See full Singulex company page
